148 related articles for article (PubMed ID: 7924883)
1. The effect of obesity on fibrinolytic activity and plasma lipoprotein (a) levels in patients with type 2 diabetes mellitus in Korea.
Park YS; Park S; Park KS; Kim SY; Lee HK; Koh CS; Min HK; Kim JQ
Diabetes Res Clin Pract; 1994 May; 24(1):25-31. PubMed ID: 7924883
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein(a), tissue plasminogen activator and plasminogen activator inhibitor 1 levels in hyperlipidaemic patients in Kuwait.
Akanji AO; Abdullah A; Tahzeeb S
Eur J Clin Invest; 1997 May; 27(5):380-6. PubMed ID: 9179544
[TBL] [Abstract][Full Text] [Related]
3. Plasma t-PA and PAI-1 antigen concentrations in non-insulin dependent diabetic patients: implication for diabetic retinopathy.
Cho YW; Yang DH; Oh DY; Baick SH; Kim SK; Kim SJ; Hong SY
Diabetes Res Clin Pract; 1994 Jan; 22(2-3):123-8. PubMed ID: 8200293
[TBL] [Abstract][Full Text] [Related]
4. Fibronectin and lipoprotein(a) are inversely related to plasminogen activator inhibitor type-1 levels in Type 2 diabetic patients without complications.
Testa R; Bonfigli AR; Sirolla C; De Grazia G; Compagnucci P; Manfrini S; Fumelli D; Testa I
Diabetes Nutr Metab; 2000 Oct; 13(5):269-75. PubMed ID: 11105969
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolysis and diabetic retinopathy in NIDDM.
Mansfield MW; Grant PJ
Diabetes Care; 1995 Dec; 18(12):1577-81. PubMed ID: 8722054
[TBL] [Abstract][Full Text] [Related]
6. Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction.
Mansfield MW; Catto AJ; Carter AM; Grant PJ
Diabet Med; 1998 Nov; 15(11):953-7. PubMed ID: 9827850
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting fibrinolytic potential: cardiovascular fitness, body composition, and lipoprotein(a).
Szymanski LM; Durstine JL; Davis PG; Dowda M; Pate RR
Metabolism; 1996 Nov; 45(11):1427-33. PubMed ID: 8931650
[TBL] [Abstract][Full Text] [Related]
8. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolytic parameters, lipid status and lipoprotein(a) in ischemic stroke patients.
Vucković BA; Djerić MJ; Ilić TA; Canak VB; Kojić-Damjanov SLj; Zarkov MG; Cabarkapa VS
Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():12-7. PubMed ID: 20229676
[TBL] [Abstract][Full Text] [Related]
10. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
Aso Y; Matsumoto S; Fujiwara Y; Tayama K; Inukai T; Takemura Y
Metabolism; 2002 Apr; 51(4):471-6. PubMed ID: 11912556
[TBL] [Abstract][Full Text] [Related]
11. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.
Al-Hamodi Z; Ismail IS; Saif-Ali R; Ahmed KA; Muniandy S
Cardiovasc Diabetol; 2011 Mar; 10():23. PubMed ID: 21414238
[TBL] [Abstract][Full Text] [Related]
12. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus.
Morishita E; Asakura H; Jokaji H; Saito M; Uotani C; Kumabashiri I; Yamazaki M; Aoshima K; Hashimoto T; Matsuda T
Atherosclerosis; 1996 Feb; 120(1-2):7-14. PubMed ID: 8645373
[TBL] [Abstract][Full Text] [Related]
13. [Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)].
Jokaji H; Asakura H; Saito M; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Matsuda T
Nihon Ronen Igakkai Zasshi; 1990 Nov; 27(6):699-705. PubMed ID: 2127812
[TBL] [Abstract][Full Text] [Related]
14. Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling.
Herlihy OM; Barrow BA; Grant PJ; Levy JC
Diabetologia; 2002 May; 45(5):635-41. PubMed ID: 12107743
[TBL] [Abstract][Full Text] [Related]
15. The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients.
Melidonis A; Stefanidis A; Tournis S; Manoussakis S; Handanis S; Zairis M; Dadiotis L; Foussas S
Clin Cardiol; 2000 Mar; 23(3):160-4. PubMed ID: 10761802
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
[TBL] [Abstract][Full Text] [Related]
17. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
Vukovich T; Proidl S; Knöbl P; Teufelsbauer H; Schnack C; Schernthaner G
Thromb Haemost; 1992 Sep; 68(3):253-6. PubMed ID: 1440487
[TBL] [Abstract][Full Text] [Related]
18. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients.
McGill JB; Schneider DJ; Arfken CL; Lucore CL; Sobel BE
Diabetes; 1994 Jan; 43(1):104-9. PubMed ID: 8262307
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity.
Umpaichitra V; Hussain MM; Castells S
Pediatr Res; 2005 Sep; 58(3):483-7. PubMed ID: 15901895
[TBL] [Abstract][Full Text] [Related]
20. Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes.
Jokl R; Klein RL; Lopes-Virella MF; Colwell JA
Diabetes Care; 1995 Aug; 18(8):1150-5. PubMed ID: 7587850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
